|From:||Richard Cartun <Rcartun@harthosp.org>|
Try CD22 and/or CD79a. We have seen a few patients whose B-cell lymphomas show equivocal CD20 immunoreactivity following Rituxan (?sp) anti-CD20 therapy.
>>> "Weems, Joyce" <JWEEMS@sjha.org> 06/07/01 12:20PM >>>
Anyone have info on other B cell markers besides CD20? Our pathologists are
concerned that patients receiving Anti CD20 medication may not stain
correctly with the CD20 marker. Thanks in advance! j:>)
Saint Joseph's Hospital of Atlanta
<< Previous Message | Next Message >>